Jounce Therapeutics, Inc.

JNCECIK 0001640455 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 28, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0018

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Jounce Therapeutics, Inc.

Name	Roles	Filings
Murray Richard /Ca/	OfficerDirector	5
Cole Hugh M	Officer	4
Drapkin Kimberlee C	Officer	4
Trehu Elizabeth	Officer	3
Diaz Luis	Director	2

Showing 1-5 of 16

Per pagePage 1 of 4Next

All filings

34 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
May 4, 2023	Salter-Cid Luisa Director	Holdings only	-	-	-
Apr 6, 2023	Murray Richard /Ca/ Director	SSale	39,228	$1.85	$72,572
Mar 14, 2023	Tang Kevin C 10% Owner	PPurchase	65,701	$0.994	$65,307
Jan 11, 2023	Cole Hugh M Chief Operating Officer	SSale	9,182	$1.12	$10,284
Jan 11, 2023	Drapkin Kimberlee C CFO and Treasurer	SSale	7,781	$1.12	$8,715

Showing 11-15 of 34

Per pagePrevPage 3 of 7Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value